SIOX Sio Gene Therapies Inc.

Axovant Gene Therapies Ltd. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of gene therapies for neurological diseases. Its product pipeline focus on Parkinson's Disease, GM1 gangliosidosis, and GM2 gangliosidosis such as Tay-Sachs disease and Sandhoff disease. Axovant operates through seven wholly owned subsidiaries and also has business operations in Basel, Switzerland and New York, NY. The company was founded on October 31, 2014 and is headquartered in London, United Kingdom.

$1.39  -0.02 (-1.42%)
As of 12/06/2021 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/10/2015
Outstanding shares:  72,941,507
Average volume:  759,680
Market cap:   $102,847,525
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    829399104
ISIN:        US8293991043
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.02
PS ratio:   0.00
Return on equity:   -47.26%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy